Antibacterial Activities of Iron Chelators Against Common Nosocomial Pathogens

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2012 Aug 2

PMID 22850524

Citations 65

Authors

Mitchell G Thompson

Brendan W Corey

Yuanzheng Si

David W Craft

Daniel V Zurawski

Affiliations

Soon will be listed here.

Abstract

The activities of iron chelators (deferoxamine, deferiprone, Apo6619, and VK28) were evaluated against type strains of Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Klebsiella pneumoniae, and Escherichia coli. Deferiprone, Apo6619, and VK28 each inhibited growth in standard and RPMI tissue culture medium, while deferoxamine had no effect. Additionally, time-kill assays revealed that VK28 had a bacteriostatic effect against S. aureus. Therefore, these newly developed iron chelators might provide a nontraditional approach for treatment of bacterial infections.

Citing Articles

Antimicrobial activity of iron-depriving pyoverdines against human opportunistic pathogens.

Vollenweider V, Rehm K, Chepkirui C, Perez-Berlanga M, Polymenidou M, Piel J Elife. 2024; 13.

PMID: 39693130 PMC: 11655065. DOI: 10.7554/eLife.92493.

Differential gut microbiota composition in β-Thalassemia patients and its correlation with iron overload.

Nonejuie P, Wilantho A, McDonald D, Htoo H, Chalerm J, Tripathi A Sci Rep. 2024; 14(1):23858.

PMID: 39394230 PMC: 11470119. DOI: 10.1038/s41598-024-75456-4.

Radiotracers for in situ infection imaging: Experimental considerations for in vitro microbial uptake of gallium-68-labeled siderophores.

Akter A, Cooper M, Darwesh A, Hider R, Blower P, Price N Diagn Microbiol Infect Dis. 2024; 110(4):116522.

PMID: 39340966 PMC: 11846779. DOI: 10.1016/j.diagmicrobio.2024.116522.

A Preliminary Study on the Effect of Deferoxamine on the Disruption of Bacterial Biofilms and Antimicrobial Resistance.

Temel A, Aksoyalp Z Turk J Pharm Sci. 2024; 21(4):267-273.

PMID: 39224041 PMC: 11589088. DOI: 10.4274/tjps.galenos.2023.23890.

Ironing out Persisters? Revisiting the Iron Chelation Strategy to Target Planktonic Bacterial Persisters Harboured in Carbapenem-Resistant .

Yeo J, Begam N, Leow W, Goh J, Zhong Y, Cai Y Microorganisms. 2024; 12(5).

PMID: 38792801 PMC: 11123761. DOI: 10.3390/microorganisms12050972.

References

Soummer A, Mathonnet A, Scatton O, Massault P, Paugam A, Lemiale V . Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis. Antimicrob Agents Chemother. 2008; 52(4):1585-6. PMC: 2292512. DOI: 10.1128/AAC.01611-07. View

Kim C, Shin S . Effect of iron-chelator deferiprone on the in vitro growth of staphylococci. J Korean Med Sci. 2009; 24(2):289-95. PMC: 2672130. DOI: 10.3346/jkms.2009.24.2.289. View

Debebe Z, Ammosova T, Breuer D, Lovejoy D, Kalinowski D, Kumar K . Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets--iron, cyclin-dependent kinase (CDK) 2, and CDK9. Mol Pharmacol. 2010; 79(1):185-96. PMC: 3014282. DOI: 10.1124/mol.110.069062. View

Tribble D, Conger N, Fraser S, Gleeson T, Wilkins K, Antonille T . Infection-associated clinical outcomes in hospitalized medical evacuees after traumatic injury: trauma infectious disease outcome study. J Trauma. 2011; 71(1 Suppl):S33-42. PMC: 4265636. DOI: 10.1097/TA.0b013e318221162e. View

van Asbeck B, Georgiou N, van der Bruggen T, Oudshoorn M, Nottet H, Marx J . Anti-HIV effect of iron chelators: different mechanisms involved. J Clin Virol. 2001; 20(3):141-7. DOI: 10.1016/s1386-6532(00)00122-0. View

Chan G, Chan S, Ho P, Ha S . Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. Hemoglobin. 2009; 33(5):352-60. DOI: 10.3109/03630260903211888. View

Lewis R, Pongas G, Albert N, Ben-Ami R, Walsh T, Kontoyiannis D . Activity of deferasirox in Mucorales: influences of species and exogenous iron. Antimicrob Agents Chemother. 2010; 55(1):411-3. PMC: 3019624. DOI: 10.1128/AAC.00792-10. View

Heli H, Mirtorabi S, Karimian K . Advances in iron chelation: an update. Expert Opin Ther Pat. 2011; 21(6):819-56. DOI: 10.1517/13543776.2011.569493. View

White R, Burgess D, Manduru M, Bosso J . Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother. 1996; 40(8):1914-8. PMC: 163439. DOI: 10.1128/AAC.40.8.1914. View

10.

Kontoghiorghes G . A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients. Hemoglobin. 2011; 35(3):301-11. DOI: 10.3109/03630269.2011.576906. View

11.

Walcourt A, Loyevsky M, Lovejoy D, Gordeuk V, Richardson D . Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites. Int J Biochem Cell Biol. 2003; 36(3):401-7. DOI: 10.1016/s1357-2725(03)00248-6. View

12.

Boucher H, Talbot G, Bradley J, Edwards J, Gilbert D, Rice L . Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2008; 48(1):1-12. DOI: 10.1086/595011. View

13.

Zarember K, Cruz A, Huang C, Gallin J . Antifungal activities of natural and synthetic iron chelators alone and in combination with azole and polyene antibiotics against Aspergillus fumigatus. Antimicrob Agents Chemother. 2009; 53(6):2654-6. PMC: 2687209. DOI: 10.1128/AAC.01547-08. View

14.

Reyes H, Tingle E, Fenves A, Spiegel J, Burton E . Pulmonary invasive mucormycosis in a patient with secondary iron overload following deferoxamine therapy. Proc (Bayl Univ Med Cent). 2008; 21(4):378-81. PMC: 2566908. DOI: 10.1080/08998280.2008.11928431. View

15.

Qiu D, Huang Z, Zhou T, Shen C, Hider R . In vitro inhibition of bacterial growth by iron chelators. FEMS Microbiol Lett. 2010; 314(2):107-11. DOI: 10.1111/j.1574-6968.2010.02153.x. View

16.

Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher H, Scheld W . The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46(2):155-64. DOI: 10.1086/524891. View

17.

Neupane G, Kim D . In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus. Eur J Clin Microbiol Infect Dis. 2010; 29(4):407-10. DOI: 10.1007/s10096-010-0875-5. View

18.

Brown T, Hawksworth J, Sheppard F, Tadaki D, Elster E . Inflammatory response is associated with critical colonization in combat wounds. Surg Infect (Larchmt). 2011; 12(5):351-7. DOI: 10.1089/sur.2010.110. View

19.

Chakrabarty P, Rudra S, Hossain M, Bhuiyan M, Khaleque M, Haque M . Iron chelation therapy and thalassemia - an overview. Mymensingh Med J. 2011; 20(3):513-9. View

20.

Collins H, Kaufmann S, Schaible U . Iron chelation via deferoxamine exacerbates experimental salmonellosis via inhibition of the nicotinamide adenine dinucleotide phosphate oxidase-dependent respiratory burst. J Immunol. 2002; 168(7):3458-63. DOI: 10.4049/jimmunol.168.7.3458. View